Drug
Velpatasvir clinical trials
Also written GS-5816.
- studies test it
- 53
- open now
- 1
- in phase 3
- 14
- first study started
- 2012
Keep track of what changes. Save the velpatasvir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
53 studies that test it; most in 2016 (8)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 7 |
| 2016 | 8 |
| 2017 | 8 |
| 2018 | 5 |
| 2019 | 6 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 19
- Phase 3
- 14
- Phase 4
- 13
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 28 · Other 25
Gilead Sciences (27) · Kirby Institute (3) · Catherine Anne Chappell (1) · Amit D Tevar, MD (1) · Mary E. Keebler, MD (1) · Fernanda P Silveira, MD, MS (1) · Elizabeth Krans, MD (1) · Alexandria University (1)
Often tested with
Tested in the same studies.
Sofosbuvir (48) · Voxilaprevir (9) · Ribavirin (9) · Sofosbuvir velpatasvir voxilaprevir drug combination (2) · Ledipasvir, sofosbuvir drug combination (2) · Ledipasvir (1) · Glecaprevir and pibrentasvir (1) · CDI-31244 (1)
Studies
Open first, then newest update. How each study uses velpatasvir is read from its arms, and is right about nine times in ten.
Testing it · 53
- Hepatitis C Treatment in Idaho County JailsNot yet recruitingNot applicableEastern Idaho Public HealthNCT06533319Written as sofosbuvir/velpatasvir
- Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During PregnancyActive, not recruitingPhase 4Catherine Anne ChappellNCT05140941Written as Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
- Expanding the Pool in Orthotopic Heart TransplantationCompletedPhase 2Mary E. Keebler, MDNCT03222531Written as sofosbuvir/velpatasvir
- The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant RecipientsCompletedPhase 2Fernanda P Silveira, MD, MSNCT03819322Written as sofosbuvir/velpatasvir
- The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant RecipientsActive, not recruitingPhase 2Amit D Tevar, MDNCT03809533Written as sofosbuvir/velpatasvir
- Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral TherapyTerminatedPhase 4M.D. Anderson Cancer CenterNCT05717400Written as Velpatasvir
- Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)Status unknownPhase 4Macfarlane Burnet Institute for Medical Research and Public Health LtdNCT05016609Written as Sofosbuvir/Velpatasvir (Gilead)
- Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C InfectionCompletedPhase 4Elizabeth Krans, MDNCT03057847Written as Sofosbuvir/Velpatasvir
- HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled TrialCompletedPhase 4Alexandria UniversityNCT04653818Written as Velpatasvir/Sofosbuvir
- Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV InfectionCompletedPhase 2Fondazione Italiana Linfomi - ETSNCT02836925Written as Sofosbuvir+Velpatasvir
- A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgramsCompletedNot applicableKirby InstituteNCT03492112Written as Sofosbuvir/velpatasvir
- Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated CirrhosisStatus unknownPhase 4Peking University People's HospitalNCT05467826Written as Sofosbuvir/Velpatasvir + Ribavirin
- Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated CirrhosisCompletedPhase 3Gilead SciencesNCT04112303Written as SOF/VEL
- Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA ExperienceCompletedPhase 2University of Maryland, BaltimoreNCT02745535Written as Sofosbuvir/Velpatasvir/Voxilaprevir
- deLIVER: Direct Acting Antiviral Effects on the LiverCompletedPhase 4Johns Hopkins UniversityNCT02938013Written as Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]
- Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active InfectionCompletedPhase 4Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT03512210Written as Sofosbuvir/Velpatasvir (SOF/VEL)
- Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) InfectionCompletedPhase 3Gilead SciencesNCT04211909Written as SOF/VEL
- Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in BrazilStatus unknownNot applicableHospital de Clinicas de Porto AlegreNCT04039698Written as Velpatasvir/Sofosbuvir
- The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in ChinaStatus unknownPhase 4Peking University First HospitalNCT04997564Written as Sofosbuvir / Velpatasvir
- Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/VelpatasvirCompletedPhase 2Hannover Medical SchoolNCT03818308Written as Sofosbuvir and Velpatasvir
See all 53 studies that test velpatasvir →
Given in every arm · 10 — velpatasvir is usual care beside what is tested
- Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and TanzaniaRecruitingEarly Phase 1Médecins du MondeNCT06159504Written as sofosbuvir/velpatasvir (SOF/VEL)
- Transplanting Hepatitis C Positive OrgansStatus unknownPhase 4Brigham and Women's HospitalNCT03086044Written as Sofosbuvir/velpatasvir
- Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus InfectionCompletedPhase 1Gilead SciencesNCT02185794Written as SOF/VEL
- Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV InfectionCompletedPhase 2Gilead SciencesNCT02378935Written as SOF/VEL
- Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated CirrhosisCompletedPhase 3Gilead SciencesNCT02996682Written as SOF/VEL
- Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral RegimenCompletedPhase 2Gilead SciencesNCT02536313Written as SOF/VEL/VOX
- Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and CirrhosisCompletedPhase 2Gilead SciencesNCT02781558Written as SOF/VEL
- Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B CirrhosisCompletedPhase 3Gilead SciencesNCT02201901Written as SOF/VEL
- Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV InfectionCompletedPhase 2Gilead SciencesNCT01858766Written as VEL
- Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected PatientsCompletedPhase 4National Taiwan University HospitalNCT03250910Written as Sofosbuvir and Velpatasvir
As the comparator · 1 — what is tested is compared with velpatasvir
Codes
What other systems call velpatasvir · ClinicalTrials.gg INT000378
- MeSH (NLM) C000604171velpatasvirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) KCU0C7RS7ZVELPATASVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1799206Confirmed FDA, Wikidata
- Wikidata Q25018296velpatasvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152851VelpatasvirOne source FDA
- DrugBank DB11613One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604171 | velpatasvir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | KCU0C7RS7Z | VELPATASVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1799206 | — | Confirmed FDA, Wikidata |
| Wikidata | Q25018296 | velpatasvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152851 | Velpatasvir | One source FDA |
| DrugBank | DB11613 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.